Mesoblast Ltd (ASX: MSB) Share Price and News

Price

 

Movement

   

  (20 mins delayed)

52 Week Range

  -  

 
1 Year Return

 

Mesoblast Ltd Chart and Price Data

Fundamentals Data provided by Morningstar.

Data provided by Morningstar.
Market Cap $563.12 million
P/E Ratio 0.14
Dividend Yield 0.00%
Shares Outstanding 1.01 billion
Earnings per share -0.087
Dividend per share N/A
Year To Date Return 54.84%
Earnings Yield 711.28%
Franking -
Share Price

Day Change

52 Week Range

-

Yesterday's Close

Today's Open

Days Range

-

Volume

Avg. Volume (1 month)

Turnover

as at 24 Feb 3:44pm

  • Mesoblast Ltd (ASX: MSB)
    Latest News

    most shorted shares webjet
    Share Market News

    These are the 10 most shorted ASX shares

    Short sellers are currently targeting these ASX shares...

    Read more »

    The words short selling in red against a black background
    Share Market News

    These are the 10 most shorted ASX shares

    Short sellers are currently targeting these ASX shares...

    Read more »

    most shorted ASX shares
    Share Market News

    These are the 10 most shorted ASX shares

    Short sellers are currently targeting these ASX shares...

    Read more »

    Green arrow going up on stock market chart, symbolising a rising share price.
    Share Gainers

    Why Brickworks, JB Hi-Fi, Mesoblast, and Sayona shares are charging higher

    These ASX shares are on form on Thursday...

    Read more »

    high, climbing, record high
    Healthcare Shares

    Here's why the Mesoblast (ASX:MSB) share price is climbing today

    Investors appear pleased.

    Read more »

    Share Market News

    These are the 10 most shorted ASX shares

    Short sellers are currently targeting these ASX shares...

    Read more »

    most shorted shares webjet
    Share Market News

    These are the 10 most shorted ASX shares

    Short sellers are currently targeting these ASX shares...

    Read more »

    Rocket powering up and symbolising a rising share price.
    Share Gainers

    These were the best performing ASX 200 shares last week

    These ASX 200 shares were on form last week...

    Read more »

    A male sharemarket analyst sits at his desk looking intently at his laptop with two other monitors next to him showing stock price movements
    Share Market News

    ASX 200 (ASX:XJO) midday update: Block falls, Nickel Mines jumps

    Here's what is happening on the ASX 200 today...

    Read more »

    Three Archer Materials scientists wearing white coats and blue gloves dance together in their lab after making a discovery
    Share Gainers

    Mesoblast (ASX:MSB) share price rebounds 15%, what's been happening?

    Shares in this biotech are bouncing back today...

    Read more »

    A young child stands against a wall holding measuring tape behind them as they wish not to be so short
    Share Market News

    These are the 10 most shorted ASX shares

    Short sellers are currently targeting these ASX shares...

    Read more »

    Two brokers pointing and analysing a share price.
    Share Market News

    These ASX 200 shares are being dumped out of the index and replaced with…

    The ASX 200 is rebalancing...

    Read more »

    Frequently Asked Questions

    No, Mesoblast does not pay shareholder dividends at this time.

    Yes, Mesoblast is listed on the ASX and the US Nasdaq under the ticker code NASDAQ: MESO.

    Mesoblast Ltd listed on the ASX on 16 December 2004.

    MSB ASX Announcements

    An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.

    DateAnnouncementPrice Sensitive?TimeNo. of PagesFile Size
    YesNo

    About Mesoblast Ltd

    Mesoblast Ltd (ASX: MSB) is a clinical-stage biotechnology company. It develops and commercialises allogeneic cellular medicines to treat complex diseases resistant to conventional standards of care.

    Its portfolio of Phase 3 product candidates includes its flagship remestemcel-L for the treatment of steroid-refractory acute graft versus host disease (SR-aGVHD) as well as moderate to severe acute respiratory distress syndrome (ARDS). Its other candidates include REVASCOR® for advanced chronic heart failure and MPC-06-ID for chronic low back pain due to degenerative disc disease. These cell therapy candidates are towards the latter stages of their clinical trial pipelines. 

    Mesoblast has locations in Australia, the United States, and Singapore and is dual-listed on the ASX and the US Nasdaq (NASDAQ: MESO).

    MSB Share Price History Data provided by Morningstar.

    Data provided by Morningstar.
    Date Close Change % Change Volume Open High Low
    27 Mar 2024 $0.50 $0.02 4.17% 60,256,032 $0.56 $0.57 $0.47
    26 Mar 2024 $0.48 $0.15 45.45% 59,011,527 $0.37 $0.52 $0.37
    25 Mar 2024 $0.33 $-0.01 -2.99% 1,717,756 $0.34 $0.34 $0.33
    22 Mar 2024 $0.34 $0.01 3.03% 1,795,037 $0.34 $0.34 $0.33
    21 Mar 2024 $0.33 $-0.01 -2.99% 4,782,124 $0.35 $0.35 $0.33
    20 Mar 2024 $0.34 $0.00 0.00% 4,214,841 $0.34 $0.35 $0.33
    19 Mar 2024 $0.34 $-0.01 -2.94% 4,536,685 $0.34 $0.35 $0.33
    18 Mar 2024 $0.34 $-0.02 -5.63% 6,067,364 $0.36 $0.36 $0.34
    15 Mar 2024 $0.36 $-0.02 -5.41% 8,902,757 $0.37 $0.37 $0.35
    14 Mar 2024 $0.37 $-0.01 -2.67% 7,346,263 $0.37 $0.40 $0.35
    13 Mar 2024 $0.38 $-0.02 -5.06% 9,241,129 $0.40 $0.41 $0.37
    12 Mar 2024 $0.40 $0.08 25.00% 25,324,652 $0.36 $0.41 $0.34
    11 Mar 2024 $0.32 $0.01 3.17% 23,986,988 $0.35 $0.37 $0.32
    08 Mar 2024 $0.32 $-0.03 -8.82% 4,972,251 $0.35 $0.35 $0.31
    07 Mar 2024 $0.34 $0.03 9.68% 9,791,441 $0.32 $0.35 $0.31
    06 Mar 2024 $0.31 $0.01 3.33% 3,630,933 $0.30 $0.32 $0.30
    05 Mar 2024 $0.30 $0.01 3.39% 2,570,523 $0.30 $0.31 $0.30
    04 Mar 2024 $0.30 $0.00 0.00% 3,796,721 $0.30 $0.31 $0.29
    01 Mar 2024 $0.30 $0.00 0.00% 1,908,221 $0.30 $0.30 $0.29
    29 Feb 2024 $0.30 $-0.01 -3.33% 3,887,970 $0.31 $0.31 $0.29
    28 Feb 2024 $0.30 $0.01 3.39% 2,944,067 $0.30 $0.31 $0.30
    27 Feb 2024 $0.30 $0.00 0.00% 1,130,265 $0.30 $0.30 $0.29

    Director Transactions Data provided by Morningstar.

    Data provided by Morningstar.
    Date Director Type Amount Value Notes
    10 Jan 2024 Silviu Itescu Issued 3,693,070 $1,052,524
    Issue of options.
    10 Jan 2024 Eric Rose Issued 1,960,765 $558,818
    Issue of options.
    10 Jan 2024 William (Bill) Burns Issued 409,651 $116,750
    Issue of options.
    10 Jan 2024 Jane Bell Issued 326,729 $93,117
    Issue of options.
    10 Jan 2024 Joseph Swedish Issued 827,077 $235,716
    Issue of options.
    10 Jan 2024 Philip Facchina Issued 290,432 $82,773
    Issue of options.
    29 Dec 2023 Joseph Swedish Buy 850 $917
    On-market trade. US$
    28 Dec 2023 Philip Krause Buy 37,500 $41,536
    On-market trade. US$
    28 Dec 2023 Joseph Swedish Buy 91,035 $99,082
    On-market trade. US$
    28 Dec 2023 Jane Bell Issued 61,905 $18,571
    Rights issue.
    28 Dec 2023 William (Bill) Burns Issued 21,250 $6,375
    Rights issue.
    21 Dec 2023 Philip Facchina Sell 30,000 $32,395
    On-market trade. US$, As per announcement on 28-12-2023
    12 Dec 2023 Silviu Itescu Issued 10,000,000 $3,000,000
    Rights issue.
    07 Jul 2023 Silviu Itescu Issued 2,325,000 $2,627,250
    Issue of options.
    07 Jul 2023 Eric Rose Issued 2,150,000 $2,429,500
    Issue of options.
    05 Jun 2023 Philip Krause Buy 20,000 $74,100
    On-market trade. US$, 100,000 ordinary shares held in the form of 20,000 ADSs

    Directors & Management Data provided by Morningstar.

    Data provided by Morningstar.
    Name Title Start Date Profile
    Professor Silviu Itescu Chief Executive OfficerExecutive Director Jun 2004
    Dr. Itescu has served on the Board of Directors since the Company's founding. Dr Itescu established an international reputation as a physician scientist in the fields of stem cell biology, autoimmune diseases, organ transplantation, and heart failure. Dr Itescu has been a faculty member of Columbia University in New York, and the University of Melbourne and Monash University in Australia. In 2013, Dr Itescu received the inaugural Key Innovator Award from the Vatican's Pontifical Council for Culture for his leadership in translational science and clinical medicine in relation to adult stem cell therapy.
    Dr Eric A Rose Non-Executive Director Apr 2013
    Dr. Rose is a highly respected physician scientist with focus on clinical investigation, drug discovery, biodefense, and health policy. As a world renowned heart surgeon and scientist, Dr. Rose led the Columbia Presbyterian heart transplantation program from 1982 through 1992 and made history in 1984 when he performed the first successful pediatric heart transplant. From 1994 through 2007, he served as Chairman of Columbia University's Department of Surgery and Surgeon in Chief of Columbia Presbyterian Medical Center in New York.
    Mr William (Bill) A Burns Non-Executive DirectorVice-Chairman Mar 2014
    Mr. Burns pent his entire management career at the Beecham Group and F. Hoffmann La Roche Ltd. Mr Burns was Chief Executive Officer of Roche Pharmaceuticals from 2001 to 2009, when he joined the Board of Directors of F. Hoffmann La Roche until he retired in 2014. He is the Chair of Molecular Partners, and has been a Non Executive Director of Shire PLC, Chugai Pharmaceutical Co., Genentech, Crucell, and Chairman of Biotie Therapies Corp. from 2014 until its sale to Acorda Therapeutics Inc. in 2016.
    Ms Jane Catherine Bell Non-Executive Director Aug 2022
    Ms. Bell is a banking and finance lawyer with 30 years experience in international law firms, financial services and corporate treasury operations focusing on international investment transactions in the United States, Canada, Australia and the United Kingdom. She has served as a non executive Director in a diverse range of highly regulated sectors including delivery of healthcare, life sciences, medical research, and funds management.
    Mr Joseph R Swedish Non-Executive DirectorNon-Executive Chairman Jun 2018
    Mr Swedish has more than two decades of healthcare leadership experience as the CEO for major United States healthcare enterprises. For 12 consecutive years, Modern Healthcare named Mr Swedish as one of the 100 Most Influential People in Healthcare, ranking in the top 20 of the health sector's most senior level executives, highlevel government administrators, elected officials, academics, and thought leaders for five consecutive years. Prior to joining Anthem, Mr. Swedish was CEO for several major integrated healthcare delivery systems.
    Mr Philip J. Facchina Non-Executive Director Mar 2021
    Mr. Facchina brings more than 35 years of experience in corporate strategy, finance, and business development across several industries, including healthcare. Since 2018, Mr. Facchina has been Chief Strategy Officer at SurgCenter, overseeing the company's strategic relationships, including its relationships with the broad US ambulatory surgical center (ASC) market and its constituents. Prior to SurgCenter, Mr. Facchina spent two decades in the public and private capital markets, where he directly managed public and private capital transactions of equity and debt, led M&A and special advisory processes including take privates.
    Dr Philip R Krause Non-Executive Director Mar 2022
    With over 30 years of experience at the Food and Drug Administration, Dr. Krause has a unique combination of scientific, regulatory, clinical, and public health experience. He is a physician with board certification in internal medicine and infectious diseases and a researcher with over 100 publications on topics spanning clinical evaluation of vaccines, viral pathogenesis and immunology, and biological product development. He is currently an independent consultant, providing strategic and regulatory advice related to biological product development. He recently served as deputy director of FDA's Office of Vaccines Research and Review, where he led assessments of biological products for evaluation and licensure and helped to oversee the development and evaluation of all vaccines authorized and licensed in the US from 2011 to 2021.
    Ms Niva Sivakumar Joint Company Secretary Oct 2019
    -
    Mr Paul Hughes Joint Company Secretary Apr 2022
    -
    Andrew Chaponnel Chief Financial Officer (interim)
    -
    Dagmar Rosa Bjorkeson Chief Operating Officer
    -
    Peter Howard General Counsel
    -
    Justin Horst Head of Manufacturing
    -
    Geraldine Storton Head of Regulatory Affairs and Quality Management
    -
    Niva Sivakumar Joint Company Secretary
    -
    Paul Hughes Joint Company Secretary
    -
    Michael Schuster Pharma Partnering
    -
    Paul Simmons Scientific Advisor to the Chief Executive Officer
    -

    Top Shareholders Data provided by Morningstar.

    Data provided by Morningstar.
    Name Shares Capital
    J P Morgan Nominees Australia Pty Limited 203,355,244 25.04%
    Hsbc Custody Nominees (Australia) Limited 84,795,597 10.44%
    Professor Silviu Itescu 67,751,838 8.34%
    Citicorp Nominees Pty Limited 36,878,513 4.54%
    Ubs Nominees Pty Ltd 14,530,688 1.79%
    Bnp Paribas Noms Pty Ltd 12,675,143 1.56%
    Thorney Holdings Pty Ltd 10,000,000 1.23%
    Tiga Trading Pty Ltd 10,000,000 1.23%
    Independent Asset Management Pty Limited 7,585,558 0.93%
    Merrill Lynch (Australia) Nominees Pty Limited 5,611,867 0.69%
    National Nominees Limited 4,014,582 0.49%
    Mr Gregory John Matthews & Mrs Janine Marie Matthews 3,841,063 0.47%
    Bnp Paribas Nominees Pty Ltd 3,484,343 0.43%
    Mann Securities Pty Ltd 2,352,942 0.29%
    Lalp Pty Ltd 1,647,144 0.20%
    Dr Siong Wei Hong 1,501,886 0.18%
    Irwin Biotech Nominees Pty Ltd 1,400,000 0.17%
    Beth Sackstein 1,277,210 0.16%
    Mr Muthiah John Hilbert 1,240,801 0.15%
    Bnp Paribas Nominees Pty Ltd Acf Clearstream 1,204,900 0.15%
    Mr Fei Tian 1,200,000 0.15%

    Profile

    since

    Note